Linked Life Data

15869446

Source:http://linkedlifedata.com/resource/pubmed/id/15869446

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2005-5-4
pubmed:abstractText
In either heavily pretreated or previously untreated patient populations, dosimetry holds the promise of playing an integral role in the physician's ability to adjust therapeutic activity prescriptions to limit excessive hematologic toxicity in individual patients. However, red marrow absorbed doses have not been highly predictive of hematopoietic toxicity. Although the accuracy of red marrow dose estimates is expected to improve as more patient-specific models are implemented, these model-calculated absorbed doses more than likely will have to be adjusted by parameters that adequately characterize bone marrow tolerance in the heavily pretreated patients most likely to receive nonmyeloablative radiolabeled antibody therapy. Models need to be established that consider not only absorbed dose but also parameters that are indicative of pretherapy bone marrow reserve and radiosensitivity so that a clinically meaningful predictive model of hematologic toxicity can be established.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1084-9785
pubmed:author
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
126-40
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: practical aspects and limitations of red marrow dosimetry.
pubmed:affiliation
Nuclear Physics Enterprises, Wellington, FL 33414, USA. siegelja@aol.com
pubmed:publicationType
Journal Article, Review